- Home
- EMX vs INBX Comparison
EMX vs INBX Comparison
Compare EMX & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMX
- INBX
- Stock Information
- Founded
- EMX N/A
- INBX 2010
- Country
- EMX Canada
- INBX United States
- Employees
- EMX N/A
- INBX N/A
- Industry
- EMX
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- EMX
- INBX Health Care
- Exchange
- EMX Nasdaq
- INBX Nasdaq
- Market Cap
- EMX 190.7M
- INBX 218.9M
- IPO Year
- EMX N/A
- INBX 2020
- Fundamental
- Price
- EMX $1.71
- INBX $14.81
- Analyst Decision
- EMX Strong Buy
- INBX Hold
- Analyst Count
- EMX 1
- INBX 1
- Target Price
- EMX $7.00
- INBX N/A
- AVG Volume (30 Days)
- EMX 235.3K
- INBX 71.2K
- Earning Date
- EMX 11-07-2024
- INBX 11-14-2024
- Dividend Yield
- EMX N/A
- INBX N/A
- EPS Growth
- EMX N/A
- INBX N/A
- EPS
- EMX N/A
- INBX 119.38
- Revenue
- EMX $26,818,000.00
- INBX $1,568,000.00
- Revenue This Year
- EMX N/A
- INBX N/A
- Revenue Next Year
- EMX $13.85
- INBX N/A
- P/E Ratio
- EMX N/A
- INBX $0.12
- Revenue Growth
- EMX 25.53
- INBX 19.24
- 52 Week Low
- EMX $1.41
- INBX $10.80
- 52 Week High
- EMX $2.15
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- EMX 42.69
- INBX 52.04
- Support Level
- EMX $1.70
- INBX $14.19
- Resistance Level
- EMX $1.81
- INBX $15.22
- Average True Range (ATR)
- EMX 0.04
- INBX 0.66
- MACD
- EMX 0.00
- INBX 0.00
- Stochastic Oscillator
- EMX 25.06
- INBX 49.13
About EMX EMX Royalty Corporation (Canada)
EMX Royalty Corp and its subsidiaries operate as a royalty and prospect generator engaged in exploring for and generating royalties from, metals and minerals properties. The company is a precious, and base metals royalty company. The Company augments royalty generation with royalty acquisitions and strategic investments. EMX's royalty and mineral property portfolio consists of properties in North America, Europe, Turkiye, Latin America, Morocco, and Australia.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.